智通财经网·2025-12-25 10:36Core Viewpoint - Fudan Zhangjiang (688505.SH) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium for visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 1: Product Development - FZ-P001 sodium is a new chemical compound developed by the company, classified as a Class 1 innovative drug [1] - The active ingredient is a conjugate of a folate receptor-targeting small molecule and a phthalocyanine photosensitizer, designed to target malignant tumor tissues with high expression of folate receptor alpha (FRα) [1] - The drug aims to enhance surgical resection outcomes for solid tumors such as ovarian cancer and lung cancer by providing molecular targeting specificity and multi-dimensional biological sensing [1] Group 2: Clinical Application - The company plans to utilize FZ-P001 sodium to develop intraoperative fluorescence guidance technology, indicating the residual malignant tumor tissue and margin status [1] - This innovative solution is intended to facilitate precise navigation during tumor surgeries [1]